Key Points
- CFO Christopher Cline sold 20,000 shares on Dec. 1 at an average price of $35.01 for $700,200, reducing his holdings by 17.84% to 92,083 shares, per the SEC filing.
- Travere reported a strong quarter — EPS $0.28 vs. -$0.31 estimate and revenue $164.9M (up 162% YoY) — the stock is trading near its 12‑month high and analysts hold a consensus “Moderate Buy” with an average target of $38.71.
Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) CFO Christopher Cline sold 20,000 shares of the company's stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $35.01, for a total value of $700,200.00. Following the sale, the chief financial officer owned 92,083 shares in the company, valued at approximately $3,223,825.83. This represents a 17.84% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Travere Therapeutics Trading Up 2.5%
NASDAQ TVTX opened at $34.85 on Thursday. Travere Therapeutics, Inc. has a 12 month low of $12.91 and a 12 month high of $37.50. The company has a current ratio of 2.75, a quick ratio of 2.71 and a debt-to-equity ratio of 4.23. The stock has a 50 day moving average of $30.64 and a 200-day moving average of $21.96. The company has a market cap of $3.12 billion, a PE ratio of -32.88 and a beta of 0.89.
Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last posted its quarterly earnings results on Thursday, October 30th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.59. The firm had revenue of $164.86 million for the quarter, compared to analyst estimates of $106.09 million. Travere Therapeutics had a negative net margin of 20.32% and a negative return on equity of 178.68%. The company's quarterly revenue was up 162.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.70) earnings per share. On average, equities research analysts anticipate that Travere Therapeutics, Inc. will post -1.4 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of equities research analysts have recently issued reports on TVTX shares. Jefferies Financial Group set a $35.00 target price on shares of Travere Therapeutics in a report on Wednesday, September 10th. Wells Fargo & Company boosted their price target on Travere Therapeutics from $27.00 to $35.00 and gave the stock an "overweight" rating in a research report on Thursday, September 11th. Scotiabank restated an "outperform" rating on shares of Travere Therapeutics in a research note on Thursday, August 7th. Stifel Nicolaus raised their price objective on Travere Therapeutics from $20.00 to $25.00 and gave the company a "hold" rating in a research report on Friday, September 12th. Finally, Zacks Research downgraded Travere Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, November 12th. Thirteen investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $38.71.
Get Our Latest Analysis on Travere Therapeutics
Institutional Investors Weigh In On Travere Therapeutics
Several hedge funds have recently bought and sold shares of TVTX. Penn Capital Management Company LLC grew its position in shares of Travere Therapeutics by 39.7% in the third quarter. Penn Capital Management Company LLC now owns 27,004 shares of the company's stock valued at $645,000 after purchasing an additional 7,680 shares during the last quarter. CIBC Bancorp USA Inc. acquired a new stake in Travere Therapeutics during the 3rd quarter worth approximately $225,000. PharVision Advisers LLC bought a new stake in Travere Therapeutics in the 3rd quarter valued at $210,000. Voloridge Investment Management LLC boosted its stake in Travere Therapeutics by 18.7% in the 3rd quarter. Voloridge Investment Management LLC now owns 883,672 shares of the company's stock valued at $21,120,000 after purchasing an additional 139,018 shares during the period. Finally, Quarry LP grew its holdings in Travere Therapeutics by 113.7% in the 3rd quarter. Quarry LP now owns 14,960 shares of the company's stock valued at $358,000 after buying an additional 7,960 shares in the last quarter.
About Travere Therapeutics
(
Get Free Report)
Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
